Gender aspects of CGRP in migraine

被引:90
作者
Labastida-Ramirez, Alejandro [1 ]
Rubio-Beltran, Eloisa [1 ]
Villalon, Carlos M. [2 ]
MaassenVanDenBrink, Antoinette [1 ]
机构
[1] Erasmus MC, Dept Internal Med, Div Vasc Med & Pharmacol, Rotterdam, Netherlands
[2] Cinvestav IPN, Dept Farmacobiol, Unidad Sur, Mexico City, DF, Mexico
关键词
CGRP; estrogen; migraine; ovarian steroid hormones; trigeminovascular system; GENE-RELATED PEPTIDE; DORSAL-ROOT GANGLIA; RANDOMIZED CONTROLLED-TRIAL; FEMALE SEX-HORMONES; RECEPTOR ANTAGONIST TELCAGEPANT; SPINAL TRIGEMINAL NUCLEUS; DERMAL BLOOD-FLOW; CALCITONIN-GENE; MONOCLONAL-ANTIBODY; MESSENGER-RNA;
D O I
10.1177/0333102417739584
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Migraine is two to three times more prevalent in women than in men, but the mechanisms involved in this gender disparity are still poorly understood. In this respect, calcitonin gene-related peptide (CGRP) plays a key role in migraine pathophysiology and, more recently, the functional interactions between ovarian steroid hormones, CGRP and the trigeminovascular system have been recognized and studied in more detail. Aims To provide an overview of CGRP studies that have addressed gender differences utilizing animal and human migraine preclinical research models to highlight how the female trigeminovascular system responds differently in the presence of varying ovarian steroid hormones. Conclusions Gender differences are evident in migraine. Several studies indicate that fluctuations of ovarian steroid hormone (mainly estrogen) levels modulate CGRP in the trigeminovascular system during different reproductive milestones. Such interactions need to be considered when conducting future animal and human experiments, since these differences may contribute to the development of gender-specific therapies.
引用
收藏
页码:435 / 444
页数:10
相关论文
共 50 条
  • [1] CGRP inhibitors for migraine prophylaxis: a safety review
    Rivera-Mancilla, Eduardo
    Villalon, Carlos M.
    MaassenVanDenBrink, Antoinette
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (10) : 1237 - 1250
  • [2] Blocking CGRP in migraine patients - a review of pros and cons
    Deen, Marie
    Correnti, Edvige
    Kamm, Katharina
    Kelderman, Tim
    Papetti, Laura
    Rubio-Beltran, Eloisa
    Vigneri, Simone
    Edvinsson, Lars
    Brink, Antoinette Maassen Van Den
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [3] CGRP - a target for acute therapy in migraine: Clinical data
    Messina, Roberta
    Goadsby, Peter J.
    CEPHALALGIA, 2019, 39 (03) : 420 - 427
  • [4] CGRP Mechanism Antagonists and Migraine Management
    Karsan, Nazia
    Goadsby, Peter J.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2015, 15 (05) : 1 - 9
  • [5] Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor
    Blumenfeld, Andrew
    Durham, Paul L.
    Feoktistov, Alexander
    Hay, Debbie L.
    Russo, Andrew F.
    Turner, Ira
    NEUROLOGY AND THERAPY, 2021, 10 (02) : 469 - 497
  • [6] CGRP and CGRP-Receptor as Targets of Migraine Therapy: Brain Prize-2021
    Tajti, Janos
    Szok, Delia
    Nyari, Aliz
    Vecsei, Laszlo
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2022, 21 (06) : 460 - 478
  • [7] CGRP Receptor Antagonism and Migraine
    Edvinsson, Lars
    Ho, Tony W.
    NEUROTHERAPEUTICS, 2010, 7 (02) : 164 - 175
  • [8] CGRP: New Focus in Migraine
    Karli, Necdet
    Bicakci, Sebnem
    Bozkurt, Manal Mehtar
    TURKISH JOURNAL OF NEUROLOGY, 2022, 28 (01) : 1 - 5
  • [9] The Journey to Establish CGRP as a Migraine Target: A Retrospective View
    Edvinsson, Lars
    HEADACHE, 2015, 55 (09): : 1249 - 1255
  • [10] The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
    Cohen, Fred
    Yuan, Hsiangkuo
    DePoy, E. M. G.
    Silberstein, Stephen D.
    NEUROTHERAPEUTICS, 2022, 19 (03) : 922 - 930